ストックスクリーナーアプリを入手
82.24
2.42%
-2.04
アフターアワーズ：
82.30
0.06
+0.07%
前日終値:
$84.28
開ける：
$83.46
24時間の取引高:
3.66M
Relative Volume:
1.61
時価総額：
$13.02B
収益：
$4.34B
当期純損益:
$-965.00M
株価収益率:
-13.55
EPS:
-6.07
ネットキャッシュフロー:
$869.00M
1週間 パフォーマンス:
+2.33%
1か月 パフォーマンス:
+6.67%
6か月 パフォーマンス:
-42.95%
1年 パフォーマンス:
-18.61%
1日の値動き範囲:
$81.19
$83.72
1週間の範囲:
$80.29
$85.90
52週間の値動き範囲:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
ILMN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
82.24 | 12.72B | 4.34B | -965.00M | 869.00M | -6.07 |
|
TMO
Thermo Fisher Scientific Inc
|
402.82 | 148.60B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.90 | 132.07B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
513.36 | 40.34B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.92 | 30.82B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
140.33 | 23.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-04 | 繰り返されました | Citigroup | Neutral |
| 2025-02-28 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-02-10 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-02-07 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-11-12 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-10-17 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-08-28 | アップグレード | Argus | Hold → Buy |
| 2024-08-16 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | アップグレード | Barclays | Underweight → Equal Weight |
| 2024-08-14 | アップグレード | TD Cowen | Hold → Buy |
| 2024-07-10 | アップグレード | Citigroup | Neutral → Buy |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-01-16 | ダウングレード | HSBC Securities | Buy → Hold |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-12-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-12-11 | アップグレード | Citigroup | Sell → Neutral |
| 2023-11-10 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | 開始されました | Bernstein | Underperform |
| 2023-07-05 | 再開されました | JP Morgan | Neutral |
| 2023-01-25 | ダウングレード | Argus | Buy → Hold |
| 2023-01-05 | 開始されました | Scotiabank | Sector Perform |
| 2022-12-12 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-10-04 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | アップグレード | Evercore ISI | In-line → Outperform |
| 2022-08-25 | 開始されました | Credit Suisse | Neutral |
| 2022-07-13 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2022-01-18 | アップグレード | Stifel | Hold → Buy |
| 2022-01-11 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-01-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-08-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-03-31 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | 開始されました | Barclays | Underweight |
| 2020-12-22 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | アップグレード | BTIG Research | Neutral → Buy |
| 2020-10-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-09-30 | 開始されました | Atlantic Equities | Overweight |
| 2020-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | ダウングレード | Stifel | Buy → Hold |
| 2020-09-22 | ダウングレード | UBS | Buy → Neutral |
| 2020-09-21 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-09-21 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-08-07 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2020-08-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-04-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-21 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | 開始されました | Wells Fargo | Underweight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-15 | 開始されました | Stifel | Buy |
| 2019-10-25 | 開始されました | Guggenheim | Buy |
すべてを表示
Illumina Inc (ILMN) 最新ニュース
Illumina Inc (ILMN) Stock Price Down 3.31% on May 30 - GuruFocus
Genotyping Assay Market Deep Research Report Highlights Key AdvancementsIllumina, Thermo Fisher Scientific - openPR.com
Illumina’s PromoterAI unlocks rare disease clues in noncoding genome - statnews.com
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain? - Yahoo Finance
Epigenetics Market Analysis 2025-2033: Advances in DNA - openPR.com
Illumina Inc.: Tackling Global Headwinds With Strategic Market Diversification! - Smartkarma
Illumina, Inc. (ILMN) Unveils AI Breakthrough for Rare Disease Diagnosis - Yahoo Finance
Illumina introduces PromoterAI for rare disease diagnosis By Investing.com - Investing.com Canada
Illumina introduces PromoterAI for rare disease diagnosis - Investing.com Australia
Operating a speedy, high-tech NGS lab in remote Australia - Illumina
Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis - PR Newswire
Bioinformatics Market Detailed in New Research ReportThermo Fisher Scientific, Illumina - openPR.com
DNA giant Illumina spawned an ecosystem of competitors and customers - Endpoints News
Illumina widens access to cancer tests with Medicare and new CDx - Yahoo
Patent Fight Breaks Out over Genetic Sequencing - Orthopedics This Week
Illumina at Bernstein Conference: Strategic Insights and Challenges - Investing.com
Transcript : Illumina, Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-28-2025 02 - marketscreener.com
Stifel Affirms Buy Rating on Illumina (ILMN) Stock - MSN
Illumina Expands Clinical Oncology Portfolio Unlocking New Standard of Care and Access to Precision Therapies - marketscreener.com
Illumina Expands Clinical Oncology Portfolio Unlocking New Standard Of Care And Access To Precision Therapies - marketscreener.com
Gene Expression Software Market Growth Projected at CAGR of 7.8% - openPR.com
Lab-on-a-chip and Microarrays (Biochip) Market Generated - openPR.com
Illumina expands oncology portfolio with new FDA-approved test - Investing.com
Illumina expands oncology portfolio with new FDA-approved test By Investing.com - Investing.com UK
Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies - PR Newswire
Stifel maintains Illumina stock buy rating, $135 target - Investing.com
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain? - Yahoo Finance
Illumina at ESHG 2025 - Illumina
Video: How researchers are moving multiomics forward with Illumina technology - Illumina
GC Genome plans $30M IPO to diversify genomic products, suppliers - BioWorld MedTech
Microfluidic Market Is Booming Worldwide | Agilent Technologies, Inc., Illumina, Inc., Perkinelmer, Inc. - openPR.com
DNA Forensic Solution Market Size, Share & Trend, Regional - openPR.com
Single Cell Genome Sequencing Market to Witness Massive Growth - openPR.com
Illumina’s SWOT analysis: genetic giant’s stock faces China headwinds By Investing.com - Investing.com Nigeria
Illumina’s SWOT analysis: genetic giant’s stock faces China headwinds - Investing.com
Cell-Free DNA Isolation and Extraction Market - GlobeNewswire Inc.
Cathie Wood Reiterates 'Profound' AI Application In Healthcare As Researchers Discover 'Cancer Survival Outcomes' By Facial Photograph Analysis: Here Are The Stocks That Could BenefitInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), Illumina (NASDAQ:IL - Benzinga
Life Sciences Tools & Services Stocks Q1 Recap: Benchmarking Illumina (NASDAQ:ILMN) - Yahoo Finance
Tumor Profiling Market May Set New Growth Story | Illumina Inc., - openPR.com
Illumina Approves Key Proposals at Annual Meeting - TipRanks
Genotyping Market to Reach $61.6 Billion, Globally, by 2033 - openPR.com
Customized CRISPR for KJ, 10x and Illumina Lawsuits, Regeneron Bags 23andMe - Genetic Engineering and Biotechnology News
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software - MSN
Danaher, Illumina, Globalstar, and Insperity Shares Plummet, What You Need To Know - Yahoo Finance
Illumina Inc (ILMN) Stock Price Down 3.01% on May 21 - GuruFocus
miRNA Sequencing and Assays Market Research Report - GlobeNewswire
miRNA Sequencing and Assays Market Research Report 2025-2030 with Focus on 25+ Major Players Such as Abcam, HTG Molecular Diagnostics, Illumina, Lexogen, Meridian Bioscience - GlobeNewswire Inc.
Immune Repertoire Sequencing Market in 2025 Detailed Study - openPR.com
Spatial Genomics Transcriptomics Market Set to Witness - openPR.com
Bioinformatics Services Market Growth, Trends & Opportunities - openPR.com
Illumina (ILMN) Rating Reiterated with Price Target Maintained | ILMN Stock News - GuruFocus
Illumina Inc (ILMN) 財務データ
収益
当期純利益
現金流量
EPS
0.78%
1.71%
大文字化:
|
ボリューム (24 時間):